SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is drawing significant attention ahead of its earnings report, fueling a heated debate over its high valuation and dilution concerns, though bulls emphasize its strong AI execution and crucial government contracts.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is witnessing strong bullish momentum driven by fervent community speculation surrounding a potential "monumental" acquisition led by CEO Ryan Cohen, a narrative amplified by a canceled interview and investor chatter referencing figures like Michael Burry. Retail traders are actively pushing the stock, anticipating a significant breakout and transformative corporate developments.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending ahead of its Q4 earnings report, driving polarized community discussion. Many view its current low valuation as a buying opportunity, while others express deep frustration over management's performance and the stock's persistent declines amidst broader regulatory headwinds for social media platforms.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is plummeting as updated weather forecasts for mid-February predict warmer temperatures, reversing the recent cold-snap rally. This "widow maker" ETF's extreme volatility has the community debating if the sharp sell-off is a "rug pull" and considering shifting to its inverse, KOLD.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood Markets is experiencing a significant pullback, widely attributed to a broad crypto market downturn and reduced prediction market activity, sparking a community debate between those who see it as an attractive buying opportunity and others concerned about potential market manipulation or deeper issues ahead of upcoming earnings.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co is a focal point after its latest earnings report showcased strong performance in its Experiences division and growing streaming profitability, coupled with a substantial share buyback program, though this was met with a notable market reaction. Conversation centers on the company's content strategy, the ongoing CEO succession, and its future growth trajectory amidst concerns about long-term stock stagnation.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Atossa Therapeutics is trending as shareholders react with widespread anger and distrust to the confirmed 1-for-15 reverse stock split and the recently announced FDA Orphan Drug Designation for Duchenne Muscular Dystrophy. The community is actively debating if the new designation is a positive catalyst or merely a distraction from concerns over impending dilution and management's perceived missteps.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following recent analyst upgrades and price target increases, driven by its proprietary silicon anode battery technology. The community is actively discussing AMPX's role in the growing drone and electric mobility sectors, with many anticipating significant contract announcements and continued upward momentum.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending ahead of its highly anticipated earnings report, with community discussion intensely focused on whether expected record revenue growth in AI infrastructure can finally trigger a short squeeze and re-rate its perceived undervaluation, or if lingering concerns over management's past performance and margin pressure will persist.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending after a blowout earnings report that significantly surpassed expectations, with management issuing an upbeat outlook driven by robust AI-fueled demand for NAND flash and enterprise SSDs, sparking numerous analyst price target upgrades. The stock's parabolic ascent has ignited a fierce debate within the community, with many bullish on the memory supercycle while others warn of an overbought market and impending crash, leading to intense trading activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$KAPA TRACON $TCON originally developed Carotuximab for Sarcoma which didn&#39;t do well in trials. However, Kairos emphasizes ENV105’s role in resistance reversal for current Prostate, Lung, Head, Neck, Breast and Colon cancers that have already confirmed good results. Whether this redirection of use is a licensing agreement, buyout or partnership is unclear.  Every interview with this CEO hints at partnerships. $TCON was liquidated in 2024 so it would be assumed that $KAPA would be the current licensed holder of Carotuximab (rebranded as ENV105) for Prostate targeted drugs, not Sarcoma. This is why revenue would go directly to Kairos Pharma and current/future partnerships.

Xavier Lopez

$KAPA  Novice question. How would KAPA make money with ENV105 (carotuximab). Since they don&#39;t own or manufacture the drug. It&#39;s currently available in research grade quantities from certain pharmaceutical suppliers (link to a supplier is attached). Would it be a licensing or right-to-use for specific drug combinations? Not familiar with that type situation. https://www.antibodysystem.com/product/220.html

Where to buy Research grade Biosimilars? Where to buy/Purchase Carotuximab biosimilar for research use? Buy research grade Carotuximab biosimilar on antibodysystem.com, anti-TRC-105, c-SN6j， antibody. Carotuximab biosimilar is available from antibodysystem. Tags: Carotuximab supplier,Carotuximab purchase,Carotuximab manufacturer,Carotuximab distributor,Carotuximab cost,Carotuximab buy,Carotuximab for sale

Buy research grade Carotuximab biosimilar ，anti-TRC-105, c-SN6j, antibody

StockTwits For Android 

Kairos Pharma Ltd.

w Cgu

StockTwits Web

TRACON Pharmaceuticals Inc

 originally developed Carotuximab for Sarcoma which didn't do well in trials. However, Kairos emphasizes ENV105’s role in resistance reversal for current Prostate, Lung, Head, Neck, Breast and Colon cancers that have already confirmed good results. Whether this redirection of use is a licensing agreement, buyout or partnership is unclear.  Every interview with this CEO hints at partnerships. 

 was liquidated in 2024 so it would be assumed that 

 would be the current licensed holder of Carotuximab (rebranded as ENV105) for Prostate targeted drugs, not Sarcoma. This is why revenue would go directly to Kairos Pharma and current/future partnerships.

SMX (Security Matters) PLC

Applied Dna Sciences Inc

Opendoor Technologies Inc

Taysha Gene Therapies Inc

NextNRG Inc.

AtlasClear Holdings Inc

Alto Neuroscience Inc.

HB Seth

@hbseth  Tracon was an original US developer of carotuximab, ran into financial difficulty arising from non-related trials. Enviro Therapeutics subsequently became developer of Tracon&#39;s IP, Enviro folded into Kairos (KAPA). In the US trials &quot;carotuximab&quot; means TRC105 for Tracon, also means ENV105 for Enviro and Kairos).  Carotuximab is being evaluated in other countries by other entities for potential uses (Australia, China, other).

  Tracon was an original US developer of carotuximab, ran into financial difficulty arising from non-related trials. Enviro Therapeutics subsequently became developer of Tracon's IP, Enviro folded into Kairos (KAPA). In the US trials "carotuximab" means TRC105 for Tracon, also means ENV105 for Enviro and Kairos).  Carotuximab is being evaluated in other countries by other entities for potential uses (Australia, China, other).

@Oldshoe Nice find! Circling back without going to deep into the woods here. As patent holders, ENV and KROS could generate billions in sales by $KAPA licensing to larger pharmaceutical companies for upfront payments, milestone payments, and royalties on sales. I hope this answers your original question.

 Nice find! Circling back without going to deep into the woods here. As patent holders, ENV and KROS could generate billions in sales by 

 licensing to larger pharmaceutical companies for upfront payments, milestone payments, and royalties on sales. I hope this answers your original question.